Genetic liability between COVID-19 and pre-eclampsia/eclampsia: a Mendelian randomization study.

Publication date: Dec 01, 2023

The aim of this study was to investigate the possible causal relationship between COVID-19 and the risk of pre-eclampsia/eclampsia using a Mendelian randomized (MR) design. We estimated their genetic correlations and then performed two-sample Mendelian randomization analyses using pooled statistics from the COVID-19 susceptibility/hospitalization genome-wide association study and the pre-eclampsia/eclampsia datasets. The main analyses were performed using the inverse variance weighting method, supplemented by the weighted median method and the MR-Egger method. We identified a significant and positive genetic correlation between COVID-19 susceptibility and pre-eclampsia/eclampsia [OR = 1. 23 (1. 01-1. 51), p = 0. 043]. Meanwhile, hospitalization of COVID-19 was significantly associated with a higher risk of pre-eclampsia/eclampsia [OR = 1. 15 (1. 02-1. 30), p = 0. 024]. Consistently, hospitalization of COVID-19 were nominally associated with higher risk of pre-eclampsia [OR = 1. 14, (1. 01-1. 30), p = 0. 040]. The results were robust under all sensitivity analyses. These results suggest that COVID-19 may increase the risk of pre-eclampsia/eclampsia. Future development of preventive or therapeutic interventions should emphasize this to mitigate the complications of COVID-19. [Figure: see text].

Concepts Keywords
Future COVID-19
Genetic eclampsia
Hospitalization Mendelian randomizations
Mendelian pre-eclampsia


Type Source Name
disease MESH COVID-19
disease MESH pre-eclampsia
disease MESH eclampsia
disease IDO susceptibility
disease MESH complications
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)